查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1266520

癌症单克隆抗体市场：按抗体类型、应用、最终用户分类：2021-2031 年全球机遇分析和行业预测

Cancer Monoclonal Antibodies Market By Antibody Type, By Application, By End User : Global Opportunity Analysis and Industry Forecast, 2021-2031
出版日期: | 出版商: Allied Market Research | 英文 300 Pages | 商品交期: 2-3个工作天内

价格

预计2021年全球癌症单克隆抗体检测市场规模为556.4亿美元，2031年收入为1068.251亿美元，复合年增长率为7.0%。

单克隆抗体是针对人体内特定部位的合成抗体。 它在致癌细胞表面起着抗原的作用。 有多种类型的单克隆抗体，每种都设计为仅结合一种类型的抗原。 这种抗体通常用于治疗多种疾病，包括癌症。 这种抗体将放射性物质和注射药物直接输送到癌细胞。 根据一项研究，放射癌症治疗是全世界最常用的癌症治疗方法之一。

不断增长的老年人口、不断上升的癌症发病率、不断增加的对新疫苗和治疗的需求是预计将推动癌症单克隆抗体检测市场增长的一些主要因素。 随着肺癌等各类癌症在全球范围内的患病率上升，对有效治疗的需求增加，促使研究人员和科学家加快研究力度，寻找有效的癌症治疗方法，现在我们正在生产新的单克隆药物。 这些因素预计将在预测期内推动市场增长。

市场受到使用最先进技术生产单克隆抗体相关的高成本的严重限制。 复杂的製造程序、昂贵的生物和化学成分、临床试验以及所需的功效、安全和质量测试是导致癌症单克隆抗体测试成本高昂的主要因素。 此外，大规模合成含有许多二硫键和翻译后修饰的单克隆抗体需要使用昂贵的专用设备。 所有这些预计将成为预测期内阻碍市场增长的主要因素。

世界各国政府都在投资开发先进的癌症诊断和治疗方法，这有望推动癌症单克隆抗体检测市场的增长。 此外，许多国家製定了旨在为其公民提供癌症治疗机会的计划和举措，进一步推动了对癌症单克隆抗体检测的需求。 政府支持的增加也导致了新的癌症单克隆抗体测试的开发，这些测试更准确、可靠且具有成本效益。 这导致早期诊断的癌症患者数量增加，增加了对癌症□□单克隆抗体检测的需求。 这促成了癌症单克隆抗体检测市场的兴起。

COVID-19 大流行对癌症单克隆抗体检测行业产生了负面影响。 在大流行的早期阶段，冠状病毒 2019 (COVID-19) 在材料供应、生产和物流运营方面造成了重大困难，并对研发活动产生了重大影响。 当 COVID-19 大流行开始时，世界上大多数公司和研究机构都关闭了，减少了对试剂和其他实验室器具的市场需求。

内容

第一章介绍

第 2 章执行摘要

第 3 章市场概述

  • 市场定义和范围
  • 主要发现
    • 顶级影响因子
    • 顶级投资基金
  • 波特的五力分析
  • 市场动态
    • 司机
    • 约束因素
    • 机会
  • 分析 COVID-19 对市场的影响
  • 主要监管分析
  • 市场份额分析
  • 专利情况
  • 监管准则
  • 价值链分析

第 4 章癌症单克隆抗体市场：按抗体类型分类

  • 概览
    • 市场规模和预测
  • 穆林
    • 主要市场趋势、增长动力和机遇
    • 市场规模和预测：按地区
    • 市场份额分析：国家/地区分析
  • 嵌合体
    • 主要市场趋势、增长动力和机遇
    • 市场规模和预测：按地区
    • 市场份额分析：国家/地区分析
  • 人性化
    • 主要市场趋势、增长动力和机遇
    • 市场规模和预测：按地区
    • 市场份额分析：国家/地区分析

第 5 章癌症单克隆抗体市场：按应用

  • 概览
    • 市场规模和预测
  • 血癌
    • 主要市场趋势、增长动力和机遇
    • 市场规模和预测：按地区
    • 市场份额分析：国家/地区分析
  • 乳腺癌
    • 主要市场趋势、增长动力和机遇
    • 市场规模和预测：按地区
    • 市场份额分析：国家/地区分析
  • 肺癌
    • 主要市场趋势、增长动力和机遇
    • 市场规模和预测：按地区
    • 市场份额分析：国家/地区分析
  • 其他
    • 主要市场趋势、增长动力和机遇
    • 市场规模和预测：按地区
    • 市场份额分析：国家/地区分析

第 6 章癌症单克隆抗体市场：按最终用户分类

  • 概览
    • 市场规模和预测
  • 医院和诊所
    • 主要市场趋势、增长动力和机遇
    • 市场规模和预测：按地区
    • 市场份额分析：国家/地区分析
  • 研究和学术机构/研究所
    • 主要市场趋势、增长动力和机遇
    • 市场规模和预测：按地区
    • 市场份额分析：国家/地区分析

第 7 章癌症单克隆抗体市场：按地区

  • 概览
    • 市场规模和预测：按地区
  • 北美
    • 主要趋势和机会
    • 市场规模和预测：按抗体类型
    • 市场规模和预测：按应用
    • 市场规模和预测：按最终用户分类
    • 市场规模/预测：按国家/地区分类
      • 美国
      • 主要市场趋势、增长动力和机遇
      • 市场规模和预测：按抗体类型
      • 市场规模和预测：按应用
      • 市场规模和预测：按最终用户分类
      • 加拿大
      • 主要市场趋势、增长动力和机遇
      • 市场规模和预测：按抗体类型
      • 市场规模和预测：按应用
      • 市场规模和预测：按最终用户分类
      • 墨西哥
      • 主要市场趋势、增长动力和机遇
      • 市场规模和预测：按抗体类型
      • 市场规模和预测：按应用
      • 市场规模和预测：按最终用户分类
  • 欧洲
    • 主要趋势和机会
    • 市场规模和预测：按抗体类型
    • 市场规模和预测：按应用
    • 市场规模和预测：按最终用户分类
    • 市场规模/预测：按国家/地区分类
      • 德国
      • 主要市场趋势、增长动力和机遇
      • 市场规模和预测：按抗体类型
      • 市场规模和预测：按应用
      • 市场规模和预测：按最终用户分类
      • 英国
      • 主要市场趋势、增长动力和机遇
      • 市场规模和预测：按抗体类型
      • 市场规模和预测：按应用
      • 市场规模和预测：按最终用户分类
      • 法国
      • 主要市场趋势、增长动力和机遇
      • 市场规模和预测：按抗体类型
      • 市场规模和预测：按应用
      • 市场规模和预测：按最终用户分类
      • 西班牙
      • 主要市场趋势、增长动力和机遇
      • 市场规模和预测：按抗体类型
      • 市场规模和预测：按应用
      • 市场规模和预测：按最终用户分类
      • 意大利
      • 主要市场趋势、增长动力和机遇
      • 市场规模和预测：按抗体类型
      • 市场规模和预测：按应用
      • 市场规模和预测：按最终用户分类
      • 其他欧洲
      • 主要市场趋势、增长动力和机遇
      • 市场规模和预测：按抗体类型
      • 市场规模和预测：按应用
      • 市场规模和预测：按最终用户分类
  • 亚太地区
    • 主要趋势和机会
    • 市场规模和预测：按抗体类型
    • 市场规模和预测：按应用
    • 市场规模和预测：按最终用户分类
    • 市场规模/预测：按国家/地区分类
      • 中国
      • 主要市场趋势、增长动力和机遇
      • 市场规模和预测：按抗体类型
      • 市场规模和预测：按应用
      • 市场规模和预测：按最终用户分类
      • 日本
      • 主要市场趋势、增长动力和机遇
      • 市场规模和预测：按抗体类型
      • 市场规模和预测：按应用
      • 市场规模和预测：按最终用户分类
      • 印度
      • 主要市场趋势、增长动力和机遇
      • 市场规模和预测：按抗体类型
      • 市场规模和预测：按应用
      • 市场规模和预测：按最终用户分类
      • 韩国
      • 主要市场趋势、增长动力和机遇
      • 市场规模和预测：按抗体类型
      • 市场规模和预测：按应用
      • 市场规模和预测：按最终用户分类
      • 澳大利亚
      • 主要市场趋势、增长动力和机遇
      • 市场规模和预测：按抗体类型
      • 市场规模和预测：按应用
      • 市场规模和预测：按最终用户分类
      • 其他亚太地区
      • 主要市场趋势、增长动力和机遇
      • 市场规模和预测：按抗体类型
      • 市场规模和预测：按应用
      • 市场规模和预测：按最终用户分类
  • 拉美
    • 主要趋势和机会
    • 市场规模和预测：按抗体类型
    • 市场规模和预测：按应用
    • 市场规模和预测：按最终用户分类
    • 市场规模/预测：按国家/地区分类
      • 巴西
      • 主要市场趋势、增长动力和机遇
      • 市场规模和预测：按抗体类型
      • 市场规模和预测：按应用
      • 市场规模和预测：按最终用户分类
      • 沙特阿拉伯
      • 主要市场趋势、增长动力和机遇
      • 市场规模和预测：按抗体类型
      • 市场规模和预测：按应用
      • 市场规模和预测：按最终用户分类
      • 阿联酋
      • 主要市场趋势、增长动力和机遇
      • 市场规模和预测：按抗体类型
      • 市场规模和预测：按应用
      • 市场规模和预测：按最终用户分类
      • 南非
      • 主要市场趋势、增长动力和机遇
      • 市场规模和预测：按抗体类型
      • 市场规模和预测：按应用
      • 市场规模和预测：按最终用户分类
      • LAMEA 的其余部分
      • 主要市场趋势、增长动力和机遇
      • 市场规模和预测：按抗体类型
      • 市场规模和预测：按应用
      • 市场规模和预测：按最终用户分类

第八章竞争格局

  • 介绍
  • 关键成功策略
  • 10 家主要公司的产品映射
  • 比赛仪表板
  • 竞争热图
  • 顶级公司定位2021

第9章 企业檔案

  • Roche Holdings Ltd
  • Johnson & Johnson
  • Pfizer Inc.
  • Novartis AG
  • AstraZeneca plc
  • Merck & Co. Inc.
  • Celgene Limited
  • Bistrol-Myers Squibb
  • Eli Lilly & Co.
  • Abbvie Inc
Product Code: A31885

The global cancer monoclonal antibody testing market size was $55,640.00 million in 2021 and is predicted to grow with a CAGR of 7.0%, by generating a revenue of $106,825.10 million by 2031.

Monoclonal antibodies are synthetic antibodies that are directed against specific sites in the human body. On the surface of the cancer-causing cells, they serve as antigens. There are numerous monoclonal antibodies, and each one is made to solely attach to one kind of antigen. These antibodies are frequently used to treat a number of illnesses, including some forms of cancer. They deliver radioactive materials or injectable medications directly to the cancer cells. According to a study, radioactive cancer therapy is the most often used type of cancer therapy worldwide.

The increase in the geriatric population, rise in the incidence of cancer, and increase in demand for novel vaccines and therapies are some of the primary factors anticipated to drive the cancer monoclonal antibody testing market growth. The demand for effective therapies has increased owing to the rise in prevalence of different types of cancer like lung cancer, around the world, prompting researchers and scientists to accelerate their research efforts and produce effective monoclonal drugs for cancer.  These factors are projected to drive the market growth during the forecast period.

The market is significantly constrained by the high costs associated with the creation of monoclonal antibodies using cutting-edge technology. The complicated manufacturing procedure, pricey biological and chemical components, clinical trials, as well as necessary efficacy, safety, and quality tests, are the main causes of the high cost of cancer monoclonal antibody testing. Large-scale synthesis of monoclonal antibodies involving many disulfide bonds and post-translational modifications necessitates the use of expensive, specialized equipment. All these are the major factors projected to hamper the market growth during the forecast period.

Governments of various countries around the world are investing in the development of advanced cancer diagnosis and treatment methods, which is expected to boost the growth of the cancer monoclonal antibody testing market. Furthermore, many countries have established programs and initiatives aimed at providing access to cancer care for their citizens, further driving the demand for cancer monoclonal antibody tests. The increase in government support is also driving the development of new cancer monoclonal antibody tests, which are more accurate, reliable, and cost-effective. This is leading to a rise in the number of cancer patients being diagnosed at an early stage, which is increasing the demand for cancer monoclonal antibody tests. This contributes to the market rise in the cancer monoclonal antibody testing market.

The COVID-19 pandemic has had a negative impact on the cancer monoclonal antibody testing industry. During the initial phase of the pandemic, the coronavirus 2019 (COVID-19), caused significant challenges in the supply of materials, production, and logistical operations, and significantly impacted research and drug development activities. When the COVID-19 pandemic began, most businesses and research initiatives around the world suspended operations, reducing market demand for reagents and other laboratory equipment.

The key players profiled in this report include: F. Hoffmann-La Roche Ltd., Bristol Myers, Squibb Co., Merck & Co., GlaxoSmithKline plc, Johnson & Johnson, Amgen, Inc., Novartis AG, AstraZeneca plc, Eli Lilly and Company, and AbbVie.

Key Benefits For Stakeholders

  • This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the cancer monoclonal antibodies market analysis from 2021 to 2031 to identify the prevailing cancer monoclonal antibodies market opportunities.
  • The market research is offered along with information related to key drivers, restraints, and opportunities.
  • Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
  • In-depth analysis of the cancer monoclonal antibodies market segmentation assists to determine the prevailing market opportunities.
  • Major countries in each region are mapped according to their revenue contribution to the global market.
  • Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
  • The report includes the analysis of the regional as well as global cancer monoclonal antibodies market trends, key players, market segments, application areas, and market growth strategies.

Key Market Segments

By End User

  • Hospitals and Clinics
  • Research and Academic Institute/Laboratories

By Antibody Type

  • Murine
  • Chimeric
  • Humanized

By Application

  • Blood Cancer
  • Breast Cancer
  • Lung Cancer
  • Others

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • France
    • Spain
    • Italy
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • Saudi Arabia
    • UAE
    • South Africa
    • Rest of LAMEA

Key Market Players

  • Roche Holdings Ltd
  • Johnson & Johnson
  • Pfizer Inc.
  • Novartis AG
  • AstraZeneca plc
  • Merck & Co. Inc.
  • Celgene Limited
  • Bistrol-Myers Squibb
  • Eli Lilly & Co.
  • Abbvie Inc

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

  • 1.1. Report description
  • 1.2. Key market segments
  • 1.3. Key benefits to the stakeholders
  • 1.4. Research Methodology
    • 1.4.1. Primary research
    • 1.4.2. Secondary research
    • 1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

  • 2.1. CXO Perspective

CHAPTER 3: MARKET OVERVIEW

  • 3.1. Market definition and scope
  • 3.2. Key findings
    • 3.2.1. Top impacting factors
    • 3.2.2. Top investment pockets
  • 3.3. Porter's five forces analysis
  • 3.4. Market dynamics
    • 3.4.1. Drivers
    • 3.4.2. Restraints
    • 3.4.3. Opportunities
  • 3.5. COVID-19 Impact Analysis on the market
  • 3.6. Key Regulation Analysis
  • 3.7. Market Share Analysis
  • 3.8. Patent Landscape
  • 3.9. Regulatory Guidelines
  • 3.10. Value Chain Analysis

CHAPTER 4: CANCER MONOCLONAL ANTIBODIES MARKET, BY ANTIBODY TYPE

  • 4.1. Overview
    • 4.1.1. Market size and forecast
  • 4.2. Murine
    • 4.2.1. Key market trends, growth factors and opportunities
    • 4.2.2. Market size and forecast, by region
    • 4.2.3. Market share analysis by country
  • 4.3. Chimeric
    • 4.3.1. Key market trends, growth factors and opportunities
    • 4.3.2. Market size and forecast, by region
    • 4.3.3. Market share analysis by country
  • 4.4. Humanized
    • 4.4.1. Key market trends, growth factors and opportunities
    • 4.4.2. Market size and forecast, by region
    • 4.4.3. Market share analysis by country

CHAPTER 5: CANCER MONOCLONAL ANTIBODIES MARKET, BY APPLICATION

  • 5.1. Overview
    • 5.1.1. Market size and forecast
  • 5.2. Blood Cancer
    • 5.2.1. Key market trends, growth factors and opportunities
    • 5.2.2. Market size and forecast, by region
    • 5.2.3. Market share analysis by country
  • 5.3. Breast Cancer
    • 5.3.1. Key market trends, growth factors and opportunities
    • 5.3.2. Market size and forecast, by region
    • 5.3.3. Market share analysis by country
  • 5.4. Lung Cancer
    • 5.4.1. Key market trends, growth factors and opportunities
    • 5.4.2. Market size and forecast, by region
    • 5.4.3. Market share analysis by country
  • 5.5. Others
    • 5.5.1. Key market trends, growth factors and opportunities
    • 5.5.2. Market size and forecast, by region
    • 5.5.3. Market share analysis by country

CHAPTER 6: CANCER MONOCLONAL ANTIBODIES MARKET, BY END USER

  • 6.1. Overview
    • 6.1.1. Market size and forecast
  • 6.2. Hospitals and Clinics
    • 6.2.1. Key market trends, growth factors and opportunities
    • 6.2.2. Market size and forecast, by region
    • 6.2.3. Market share analysis by country
  • 6.3. Research and Academic Institute/Laboratories
    • 6.3.1. Key market trends, growth factors and opportunities
    • 6.3.2. Market size and forecast, by region
    • 6.3.3. Market share analysis by country

CHAPTER 7: CANCER MONOCLONAL ANTIBODIES MARKET, BY REGION

  • 7.1. Overview
    • 7.1.1. Market size and forecast By Region
  • 7.2. North America
    • 7.2.1. Key trends and opportunities
    • 7.2.2. Market size and forecast, by Antibody Type
    • 7.2.3. Market size and forecast, by Application
    • 7.2.4. Market size and forecast, by End User
    • 7.2.5. Market size and forecast, by country
      • 7.2.5.1. U.S.
      • 7.2.5.1.1. Key market trends, growth factors and opportunities
      • 7.2.5.1.2. Market size and forecast, by Antibody Type
      • 7.2.5.1.3. Market size and forecast, by Application
      • 7.2.5.1.4. Market size and forecast, by End User
      • 7.2.5.2. Canada
      • 7.2.5.2.1. Key market trends, growth factors and opportunities
      • 7.2.5.2.2. Market size and forecast, by Antibody Type
      • 7.2.5.2.3. Market size and forecast, by Application
      • 7.2.5.2.4. Market size and forecast, by End User
      • 7.2.5.3. Mexico
      • 7.2.5.3.1. Key market trends, growth factors and opportunities
      • 7.2.5.3.2. Market size and forecast, by Antibody Type
      • 7.2.5.3.3. Market size and forecast, by Application
      • 7.2.5.3.4. Market size and forecast, by End User
  • 7.3. Europe
    • 7.3.1. Key trends and opportunities
    • 7.3.2. Market size and forecast, by Antibody Type
    • 7.3.3. Market size and forecast, by Application
    • 7.3.4. Market size and forecast, by End User
    • 7.3.5. Market size and forecast, by country
      • 7.3.5.1. Germany
      • 7.3.5.1.1. Key market trends, growth factors and opportunities
      • 7.3.5.1.2. Market size and forecast, by Antibody Type
      • 7.3.5.1.3. Market size and forecast, by Application
      • 7.3.5.1.4. Market size and forecast, by End User
      • 7.3.5.2. UK
      • 7.3.5.2.1. Key market trends, growth factors and opportunities
      • 7.3.5.2.2. Market size and forecast, by Antibody Type
      • 7.3.5.2.3. Market size and forecast, by Application
      • 7.3.5.2.4. Market size and forecast, by End User
      • 7.3.5.3. France
      • 7.3.5.3.1. Key market trends, growth factors and opportunities
      • 7.3.5.3.2. Market size and forecast, by Antibody Type
      • 7.3.5.3.3. Market size and forecast, by Application
      • 7.3.5.3.4. Market size and forecast, by End User
      • 7.3.5.4. Spain
      • 7.3.5.4.1. Key market trends, growth factors and opportunities
      • 7.3.5.4.2. Market size and forecast, by Antibody Type
      • 7.3.5.4.3. Market size and forecast, by Application
      • 7.3.5.4.4. Market size and forecast, by End User
      • 7.3.5.5. Italy
      • 7.3.5.5.1. Key market trends, growth factors and opportunities
      • 7.3.5.5.2. Market size and forecast, by Antibody Type
      • 7.3.5.5.3. Market size and forecast, by Application
      • 7.3.5.5.4. Market size and forecast, by End User
      • 7.3.5.6. Rest of Europe
      • 7.3.5.6.1. Key market trends, growth factors and opportunities
      • 7.3.5.6.2. Market size and forecast, by Antibody Type
      • 7.3.5.6.3. Market size and forecast, by Application
      • 7.3.5.6.4. Market size and forecast, by End User
  • 7.4. Asia-Pacific
    • 7.4.1. Key trends and opportunities
    • 7.4.2. Market size and forecast, by Antibody Type
    • 7.4.3. Market size and forecast, by Application
    • 7.4.4. Market size and forecast, by End User
    • 7.4.5. Market size and forecast, by country
      • 7.4.5.1. China
      • 7.4.5.1.1. Key market trends, growth factors and opportunities
      • 7.4.5.1.2. Market size and forecast, by Antibody Type
      • 7.4.5.1.3. Market size and forecast, by Application
      • 7.4.5.1.4. Market size and forecast, by End User
      • 7.4.5.2. Japan
      • 7.4.5.2.1. Key market trends, growth factors and opportunities
      • 7.4.5.2.2. Market size and forecast, by Antibody Type
      • 7.4.5.2.3. Market size and forecast, by Application
      • 7.4.5.2.4. Market size and forecast, by End User
      • 7.4.5.3. India
      • 7.4.5.3.1. Key market trends, growth factors and opportunities
      • 7.4.5.3.2. Market size and forecast, by Antibody Type
      • 7.4.5.3.3. Market size and forecast, by Application
      • 7.4.5.3.4. Market size and forecast, by End User
      • 7.4.5.4. South Korea
      • 7.4.5.4.1. Key market trends, growth factors and opportunities
      • 7.4.5.4.2. Market size and forecast, by Antibody Type
      • 7.4.5.4.3. Market size and forecast, by Application
      • 7.4.5.4.4. Market size and forecast, by End User
      • 7.4.5.5. Australia
      • 7.4.5.5.1. Key market trends, growth factors and opportunities
      • 7.4.5.5.2. Market size and forecast, by Antibody Type
      • 7.4.5.5.3. Market size and forecast, by Application
      • 7.4.5.5.4. Market size and forecast, by End User
      • 7.4.5.6. Rest of Asia-Pacific
      • 7.4.5.6.1. Key market trends, growth factors and opportunities
      • 7.4.5.6.2. Market size and forecast, by Antibody Type
      • 7.4.5.6.3. Market size and forecast, by Application
      • 7.4.5.6.4. Market size and forecast, by End User
  • 7.5. LAMEA
    • 7.5.1. Key trends and opportunities
    • 7.5.2. Market size and forecast, by Antibody Type
    • 7.5.3. Market size and forecast, by Application
    • 7.5.4. Market size and forecast, by End User
    • 7.5.5. Market size and forecast, by country
      • 7.5.5.1. Brazil
      • 7.5.5.1.1. Key market trends, growth factors and opportunities
      • 7.5.5.1.2. Market size and forecast, by Antibody Type
      • 7.5.5.1.3. Market size and forecast, by Application
      • 7.5.5.1.4. Market size and forecast, by End User
      • 7.5.5.2. Saudi Arabia
      • 7.5.5.2.1. Key market trends, growth factors and opportunities
      • 7.5.5.2.2. Market size and forecast, by Antibody Type
      • 7.5.5.2.3. Market size and forecast, by Application
      • 7.5.5.2.4. Market size and forecast, by End User
      • 7.5.5.3. UAE
      • 7.5.5.3.1. Key market trends, growth factors and opportunities
      • 7.5.5.3.2. Market size and forecast, by Antibody Type
      • 7.5.5.3.3. Market size and forecast, by Application
      • 7.5.5.3.4. Market size and forecast, by End User
      • 7.5.5.4. South Africa
      • 7.5.5.4.1. Key market trends, growth factors and opportunities
      • 7.5.5.4.2. Market size and forecast, by Antibody Type
      • 7.5.5.4.3. Market size and forecast, by Application
      • 7.5.5.4.4. Market size and forecast, by End User
      • 7.5.5.5. Rest of LAMEA
      • 7.5.5.5.1. Key market trends, growth factors and opportunities
      • 7.5.5.5.2. Market size and forecast, by Antibody Type
      • 7.5.5.5.3. Market size and forecast, by Application
      • 7.5.5.5.4. Market size and forecast, by End User

CHAPTER 8: COMPETITIVE LANDSCAPE

  • 8.1. Introduction
  • 8.2. Top winning strategies
  • 8.3. Product Mapping of Top 10 Player
  • 8.4. Competitive Dashboard
  • 8.5. Competitive Heatmap
  • 8.6. Top player positioning, 2021

CHAPTER 9: COMPANY PROFILES

  • 9.1. Roche Holdings Ltd
    • 9.1.1. Company overview
    • 9.1.2. Key Executives
    • 9.1.3. Company snapshot
  • 9.2. Johnson & Johnson
    • 9.2.1. Company overview
    • 9.2.2. Key Executives
    • 9.2.3. Company snapshot
  • 9.3. Pfizer Inc.
    • 9.3.1. Company overview
    • 9.3.2. Key Executives
    • 9.3.3. Company snapshot
  • 9.4. Novartis AG
    • 9.4.1. Company overview
    • 9.4.2. Key Executives
    • 9.4.3. Company snapshot
  • 9.5. AstraZeneca plc
    • 9.5.1. Company overview
    • 9.5.2. Key Executives
    • 9.5.3. Company snapshot
  • 9.6. Merck & Co. Inc.
    • 9.6.1. Company overview
    • 9.6.2. Key Executives
    • 9.6.3. Company snapshot
  • 9.7. Celgene Limited
    • 9.7.1. Company overview
    • 9.7.2. Key Executives
    • 9.7.3. Company snapshot
  • 9.8. Bistrol-Myers Squibb
    • 9.8.1. Company overview
    • 9.8.2. Key Executives
    • 9.8.3. Company snapshot
  • 9.9. Eli Lilly & Co.
    • 9.9.1. Company overview
    • 9.9.2. Key Executives
    • 9.9.3. Company snapshot
  • 9.10. Abbvie Inc
    • 9.10.1. Company overview
    • 9.10.2. Key Executives
    • 9.10.3. Company snapshot

LIST OF TABLES

  • TABLE 01. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET, BY ANTIBODY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 02. CANCER MONOCLONAL ANTIBODIES MARKET FOR MURINE, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 03. CANCER MONOCLONAL ANTIBODIES MARKET FOR CHIMERIC, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 04. CANCER MONOCLONAL ANTIBODIES MARKET FOR HUMANIZED, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 05. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET, BY APPLICATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 06. CANCER MONOCLONAL ANTIBODIES MARKET FOR BLOOD CANCER, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 07. CANCER MONOCLONAL ANTIBODIES MARKET FOR BREAST CANCER, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 08. CANCER MONOCLONAL ANTIBODIES MARKET FOR LUNG CANCER, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 09. CANCER MONOCLONAL ANTIBODIES MARKET FOR OTHERS, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 10. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
  • TABLE 11. CANCER MONOCLONAL ANTIBODIES MARKET FOR HOSPITALS AND CLINICS, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 12. CANCER MONOCLONAL ANTIBODIES MARKET FOR RESEARCH AND ACADEMIC INSTITUTE/LABORATORIES, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 13. CANCER MONOCLONAL ANTIBODIES MARKET, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 14. NORTH AMERICA CANCER MONOCLONAL ANTIBODIES MARKET, BY ANTIBODY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 15. NORTH AMERICA CANCER MONOCLONAL ANTIBODIES MARKET, BY APPLICATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 16. NORTH AMERICA CANCER MONOCLONAL ANTIBODIES MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
  • TABLE 17. NORTH AMERICA CANCER MONOCLONAL ANTIBODIES MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
  • TABLE 18. U.S. CANCER MONOCLONAL ANTIBODIES MARKET, BY ANTIBODY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 19. U.S. CANCER MONOCLONAL ANTIBODIES MARKET, BY APPLICATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 20. U.S. CANCER MONOCLONAL ANTIBODIES MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
  • TABLE 21. CANADA CANCER MONOCLONAL ANTIBODIES MARKET, BY ANTIBODY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 22. CANADA CANCER MONOCLONAL ANTIBODIES MARKET, BY APPLICATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 23. CANADA CANCER MONOCLONAL ANTIBODIES MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
  • TABLE 24. MEXICO CANCER MONOCLONAL ANTIBODIES MARKET, BY ANTIBODY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 25. MEXICO CANCER MONOCLONAL ANTIBODIES MARKET, BY APPLICATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 26. MEXICO CANCER MONOCLONAL ANTIBODIES MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
  • TABLE 27. EUROPE CANCER MONOCLONAL ANTIBODIES MARKET, BY ANTIBODY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 28. EUROPE CANCER MONOCLONAL ANTIBODIES MARKET, BY APPLICATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 29. EUROPE CANCER MONOCLONAL ANTIBODIES MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
  • TABLE 30. EUROPE CANCER MONOCLONAL ANTIBODIES MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
  • TABLE 31. GERMANY CANCER MONOCLONAL ANTIBODIES MARKET, BY ANTIBODY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 32. GERMANY CANCER MONOCLONAL ANTIBODIES MARKET, BY APPLICATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 33. GERMANY CANCER MONOCLONAL ANTIBODIES MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
  • TABLE 34. UK CANCER MONOCLONAL ANTIBODIES MARKET, BY ANTIBODY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 35. UK CANCER MONOCLONAL ANTIBODIES MARKET, BY APPLICATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 36. UK CANCER MONOCLONAL ANTIBODIES MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
  • TABLE 37. FRANCE CANCER MONOCLONAL ANTIBODIES MARKET, BY ANTIBODY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 38. FRANCE CANCER MONOCLONAL ANTIBODIES MARKET, BY APPLICATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 39. FRANCE CANCER MONOCLONAL ANTIBODIES MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
  • TABLE 40. SPAIN CANCER MONOCLONAL ANTIBODIES MARKET, BY ANTIBODY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 41. SPAIN CANCER MONOCLONAL ANTIBODIES MARKET, BY APPLICATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 42. SPAIN CANCER MONOCLONAL ANTIBODIES MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
  • TABLE 43. ITALY CANCER MONOCLONAL ANTIBODIES MARKET, BY ANTIBODY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 44. ITALY CANCER MONOCLONAL ANTIBODIES MARKET, BY APPLICATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 45. ITALY CANCER MONOCLONAL ANTIBODIES MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
  • TABLE 46. REST OF EUROPE CANCER MONOCLONAL ANTIBODIES MARKET, BY ANTIBODY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 47. REST OF EUROPE CANCER MONOCLONAL ANTIBODIES MARKET, BY APPLICATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 48. REST OF EUROPE CANCER MONOCLONAL ANTIBODIES MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
  • TABLE 49. ASIA-PACIFIC CANCER MONOCLONAL ANTIBODIES MARKET, BY ANTIBODY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 50. ASIA-PACIFIC CANCER MONOCLONAL ANTIBODIES MARKET, BY APPLICATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 51. ASIA-PACIFIC CANCER MONOCLONAL ANTIBODIES MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
  • TABLE 52. ASIA-PACIFIC CANCER MONOCLONAL ANTIBODIES MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
  • TABLE 53. CHINA CANCER MONOCLONAL ANTIBODIES MARKET, BY ANTIBODY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 54. CHINA CANCER MONOCLONAL ANTIBODIES MARKET, BY APPLICATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 55. CHINA CANCER MONOCLONAL ANTIBODIES MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
  • TABLE 56. JAPAN CANCER MONOCLONAL ANTIBODIES MARKET, BY ANTIBODY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 57. JAPAN CANCER MONOCLONAL ANTIBODIES MARKET, BY APPLICATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 58. JAPAN CANCER MONOCLONAL ANTIBODIES MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
  • TABLE 59. INDIA CANCER MONOCLONAL ANTIBODIES MARKET, BY ANTIBODY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 60. INDIA CANCER MONOCLONAL ANTIBODIES MARKET, BY APPLICATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 61. INDIA CANCER MONOCLONAL ANTIBODIES MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
  • TABLE 62. SOUTH KOREA CANCER MONOCLONAL ANTIBODIES MARKET, BY ANTIBODY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 63. SOUTH KOREA CANCER MONOCLONAL ANTIBODIES MARKET, BY APPLICATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 64. SOUTH KOREA CANCER MONOCLONAL ANTIBODIES MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
  • TABLE 65. AUSTRALIA CANCER MONOCLONAL ANTIBODIES MARKET, BY ANTIBODY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 66. AUSTRALIA CANCER MONOCLONAL ANTIBODIES MARKET, BY APPLICATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 67. AUSTRALIA CANCER MONOCLONAL ANTIBODIES MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
  • TABLE 68. REST OF ASIA-PACIFIC CANCER MONOCLONAL ANTIBODIES MARKET, BY ANTIBODY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 69. REST OF ASIA-PACIFIC CANCER MONOCLONAL ANTIBODIES MARKET, BY APPLICATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 70. REST OF ASIA-PACIFIC CANCER MONOCLONAL ANTIBODIES MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
  • TABLE 71. LAMEA CANCER MONOCLONAL ANTIBODIES MARKET, BY ANTIBODY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 72. LAMEA CANCER MONOCLONAL ANTIBODIES MARKET, BY APPLICATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 73. LAMEA CANCER MONOCLONAL ANTIBODIES MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
  • TABLE 74. LAMEA CANCER MONOCLONAL ANTIBODIES MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
  • TABLE 75. BRAZIL CANCER MONOCLONAL ANTIBODIES MARKET, BY ANTIBODY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 76. BRAZIL CANCER MONOCLONAL ANTIBODIES MARKET, BY APPLICATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 77. BRAZIL CANCER MONOCLONAL ANTIBODIES MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
  • TABLE 78. SAUDI ARABIA CANCER MONOCLONAL ANTIBODIES MARKET, BY ANTIBODY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 79. SAUDI ARABIA CANCER MONOCLONAL ANTIBODIES MARKET, BY APPLICATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 80. SAUDI ARABIA CANCER MONOCLONAL ANTIBODIES MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
  • TABLE 81. UAE CANCER MONOCLONAL ANTIBODIES MARKET, BY ANTIBODY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 82. UAE CANCER MONOCLONAL ANTIBODIES MARKET, BY APPLICATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 83. UAE CANCER MONOCLONAL ANTIBODIES MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
  • TABLE 84. SOUTH AFRICA CANCER MONOCLONAL ANTIBODIES MARKET, BY ANTIBODY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 85. SOUTH AFRICA CANCER MONOCLONAL ANTIBODIES MARKET, BY APPLICATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 86. SOUTH AFRICA CANCER MONOCLONAL ANTIBODIES MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
  • TABLE 87. REST OF LAMEA CANCER MONOCLONAL ANTIBODIES MARKET, BY ANTIBODY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 88. REST OF LAMEA CANCER MONOCLONAL ANTIBODIES MARKET, BY APPLICATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 89. REST OF LAMEA CANCER MONOCLONAL ANTIBODIES MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
  • TABLE 90. ROCHE HOLDINGS LTD: KEY EXECUTIVES
  • TABLE 91. ROCHE HOLDINGS LTD: COMPANY SNAPSHOT
  • TABLE 92. JOHNSON & JOHNSON: KEY EXECUTIVES
  • TABLE 93. JOHNSON & JOHNSON: COMPANY SNAPSHOT
  • TABLE 94. PFIZER INC.: KEY EXECUTIVES
  • TABLE 95. PFIZER INC.: COMPANY SNAPSHOT
  • TABLE 96. NOVARTIS AG: KEY EXECUTIVES
  • TABLE 97. NOVARTIS AG: COMPANY SNAPSHOT
  • TABLE 98. ASTRAZENECA PLC: KEY EXECUTIVES
  • TABLE 99. ASTRAZENECA PLC: COMPANY SNAPSHOT
  • TABLE 100. MERCK & CO. INC.: KEY EXECUTIVES
  • TABLE 101. MERCK & CO. INC.: COMPANY SNAPSHOT
  • TABLE 102. CELGENE LIMITED: KEY EXECUTIVES
  • TABLE 103. CELGENE LIMITED: COMPANY SNAPSHOT
  • TABLE 104. BISTROL-MYERS SQUIBB: KEY EXECUTIVES
  • TABLE 105. BISTROL-MYERS SQUIBB: COMPANY SNAPSHOT
  • TABLE 106. ELI LILLY & CO.: KEY EXECUTIVES
  • TABLE 107. ELI LILLY & CO.: COMPANY SNAPSHOT
  • TABLE 108. ABBVIE INC: KEY EXECUTIVES
  • TABLE 109. ABBVIE INC: COMPANY SNAPSHOT

LIST OF FIGURES

  • FIGURE 01. CANCER MONOCLONAL ANTIBODIES MARKET, 2021-2031
  • FIGURE 02. SEGMENTATION OF CANCER MONOCLONAL ANTIBODIES MARKET, 2021-2031
  • FIGURE 03. TOP INVESTMENT POCKETS IN CANCER MONOCLONAL ANTIBODIES MARKET (2022-2031)
  • FIGURE 04. PORTER FIVE-1
  • FIGURE 05. PORTER FIVE-2
  • FIGURE 06. PORTER FIVE-3
  • FIGURE 07. PORTER FIVE-4
  • FIGURE 08. PORTER FIVE-5
  • FIGURE 09. DRIVERS, RESTRAINTS AND OPPORTUNITIES: GLOBALCANCER MONOCLONAL ANTIBODIES MARKET
  • FIGURE 10. IMPACT OF KEY REGULATION: CANCER MONOCLONAL ANTIBODIES MARKET
  • FIGURE 11. MARKET SHARE ANALYSIS: CANCER MONOCLONAL ANTIBODIES MARKET
  • FIGURE 12. PATENT ANALYSIS BY COMPANY
  • FIGURE 13. PATENT ANALYSIS BY COUNTRY
  • FIGURE 14. REGULATORY GUIDELINES: CANCER MONOCLONAL ANTIBODIES MARKET
  • FIGURE 15. VALUE CHAIN ANALYSIS: CANCER MONOCLONAL ANTIBODIES MARKET
  • FIGURE 16. CANCER MONOCLONAL ANTIBODIES MARKET, BY ANTIBODY TYPE, 2021(%)
  • FIGURE 17. COMPARATIVE SHARE ANALYSIS OF CANCER MONOCLONAL ANTIBODIES MARKET FOR MURINE, BY COUNTRY 2021-2031(%)
  • FIGURE 18. COMPARATIVE SHARE ANALYSIS OF CANCER MONOCLONAL ANTIBODIES MARKET FOR CHIMERIC, BY COUNTRY 2021-2031(%)
  • FIGURE 19. COMPARATIVE SHARE ANALYSIS OF CANCER MONOCLONAL ANTIBODIES MARKET FOR HUMANIZED, BY COUNTRY 2021-2031(%)
  • FIGURE 20. CANCER MONOCLONAL ANTIBODIES MARKET, BY APPLICATION, 2021(%)
  • FIGURE 21. COMPARATIVE SHARE ANALYSIS OF CANCER MONOCLONAL ANTIBODIES MARKET FOR BLOOD CANCER, BY COUNTRY 2021-2031(%)
  • FIGURE 22. COMPARATIVE SHARE ANALYSIS OF CANCER MONOCLONAL ANTIBODIES MARKET FOR BREAST CANCER, BY COUNTRY 2021-2031(%)
  • FIGURE 23. COMPARATIVE SHARE ANALYSIS OF CANCER MONOCLONAL ANTIBODIES MARKET FOR LUNG CANCER, BY COUNTRY 2021-2031(%)
  • FIGURE 24. COMPARATIVE SHARE ANALYSIS OF CANCER MONOCLONAL ANTIBODIES MARKET FOR OTHERS, BY COUNTRY 2021-2031(%)
  • FIGURE 25. CANCER MONOCLONAL ANTIBODIES MARKET, BY END USER, 2021(%)
  • FIGURE 26. COMPARATIVE SHARE ANALYSIS OF CANCER MONOCLONAL ANTIBODIES MARKET FOR HOSPITALS AND CLINICS, BY COUNTRY 2021-2031(%)
  • FIGURE 27. COMPARATIVE SHARE ANALYSIS OF CANCER MONOCLONAL ANTIBODIES MARKET FOR RESEARCH AND ACADEMIC INSTITUTE/LABORATORIES, BY COUNTRY 2021-2031(%)
  • FIGURE 28. CANCER MONOCLONAL ANTIBODIES MARKET BY REGION, 2021
  • FIGURE 29. U.S. CANCER MONOCLONAL ANTIBODIES MARKET, 2021-2031 ($MILLION)
  • FIGURE 30. CANADA CANCER MONOCLONAL ANTIBODIES MARKET, 2021-2031 ($MILLION)
  • FIGURE 31. MEXICO CANCER MONOCLONAL ANTIBODIES MARKET, 2021-2031 ($MILLION)
  • FIGURE 32. GERMANY CANCER MONOCLONAL ANTIBODIES MARKET, 2021-2031 ($MILLION)
  • FIGURE 33. UK CANCER MONOCLONAL ANTIBODIES MARKET, 2021-2031 ($MILLION)
  • FIGURE 34. FRANCE CANCER MONOCLONAL ANTIBODIES MARKET, 2021-2031 ($MILLION)
  • FIGURE 35. SPAIN CANCER MONOCLONAL ANTIBODIES MARKET, 2021-2031 ($MILLION)
  • FIGURE 36. ITALY CANCER MONOCLONAL ANTIBODIES MARKET, 2021-2031 ($MILLION)
  • FIGURE 37. REST OF EUROPE CANCER MONOCLONAL ANTIBODIES MARKET, 2021-2031 ($MILLION)
  • FIGURE 38. CHINA CANCER MONOCLONAL ANTIBODIES MARKET, 2021-2031 ($MILLION)
  • FIGURE 39. JAPAN CANCER MONOCLONAL ANTIBODIES MARKET, 2021-2031 ($MILLION)
  • FIGURE 40. INDIA CANCER MONOCLONAL ANTIBODIES MARKET, 2021-2031 ($MILLION)
  • FIGURE 41. SOUTH KOREA CANCER MONOCLONAL ANTIBODIES MARKET, 2021-2031 ($MILLION)
  • FIGURE 42. AUSTRALIA CANCER MONOCLONAL ANTIBODIES MARKET, 2021-2031 ($MILLION)
  • FIGURE 43. REST OF ASIA-PACIFIC CANCER MONOCLONAL ANTIBODIES MARKET, 2021-2031 ($MILLION)
  • FIGURE 44. BRAZIL CANCER MONOCLONAL ANTIBODIES MARKET, 2021-2031 ($MILLION)
  • FIGURE 45. SAUDI ARABIA CANCER MONOCLONAL ANTIBODIES MARKET, 2021-2031 ($MILLION)
  • FIGURE 46. UAE CANCER MONOCLONAL ANTIBODIES MARKET, 2021-2031 ($MILLION)
  • FIGURE 47. SOUTH AFRICA CANCER MONOCLONAL ANTIBODIES MARKET, 2021-2031 ($MILLION)
  • FIGURE 48. REST OF LAMEA CANCER MONOCLONAL ANTIBODIES MARKET, 2021-2031 ($MILLION)
  • FIGURE 49. TOP WINNING STRATEGIES, BY YEAR
  • FIGURE 50. TOP WINNING STRATEGIES, BY DEVELOPMENT
  • FIGURE 51. TOP WINNING STRATEGIES, BY COMPANY
  • FIGURE 52. PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 53. COMPETITIVE DASHBOARD
  • FIGURE 54. COMPETITIVE HEATMAP: CANCER MONOCLONAL ANTIBODIES MARKET
  • FIGURE 55. TOP PLAYER POSITIONING, 2021